{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T21:36:31Z","timestamp":1775338591481,"version":"3.50.1"},"reference-count":144,"publisher":"Portland Press Ltd.","issue":"2","license":[{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,31]]},"abstract":"<jats:p>Chronic myeloid leukemia (CML) was considered for a long time one of the most hostile leukemia that was incurable for most of the patients, predominantly due to the extreme resistance to chemotherapy. Part of the resistance to cell death (apoptosis) is the result of increased levels of anti-apoptotic and decreased levels of pro-apoptotic member of the BCL-2 family induced by the BCR-ABL1 oncoprotein. BCR-ABL1 is a constitutively active tyrosine kinase responsible for initiating multiple and oncogenic signaling pathways. With the development of specific BCR-ABL1 tyrosine kinase inhibitors (TKIs) CML became a much more tractable disease. Nevertheless, TKIs do not cure CML patients and a substantial number of them develop intolerance or become resistant to the treatment. Therefore, novel anti-cancer strategies must be developed to treat CML patients independently or in combination with TKIs. Here, we will discuss the mechanisms of BCR-ABL1-dependent and -independent resistance to TKIs and the use of BH3-mimetics as a potential tool to fight CML.<\/jats:p>","DOI":"10.1042\/bcj20210608","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T16:10:58Z","timestamp":1675181458000},"page":"161-176","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia"],"prefix":"10.1042","volume":"480","author":[{"given":"Gabriela","family":"Brumatti","sequence":"first","affiliation":[{"name":"1Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"3Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deeksha","family":"Kaloni","sequence":"additional","affiliation":[{"name":"2Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"3Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fab\u00edola Atti\u00e9","family":"Castro","sequence":"additional","affiliation":[{"name":"4Departamento de An\u00e1lises Cl\u00ednicas, Toxicol\u00f3gicas e Bromatol\u00f3gicas, Faculdade de Ci\u00eancias Farmac\u00eauticas de Ribeir\u00e3o Preto, Universidade de S\u00e3o Paulo, Ribeir\u00e3o Preto, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7851-6205","authenticated-orcid":false,"given":"Gustavo P.","family":"Amarante-Mendes","sequence":"additional","affiliation":[{"name":"5Departamento de Imunologia, Instituto de Ci\u00eancias Biom\u00e9dicas, Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"},{"name":"6Instituto de Investiga\u00e7\u00e3o em Imunologia, Instituto Nacional de Ci\u00eancia e Tecnologia (INCT-iii), S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2023,1,31]]},"reference":[{"key":"2023020312104897200_BCJ-2021-0608CC1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/jnci\/25.1.85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","year":"1960","journal-title":"J. Natl Cancer Inst."},{"key":"2023020312104897200_BCJ-2021-0608CC2","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.V83.8.2038.2038","article-title":"Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia","volume":"83","year":"1994","journal-title":"Blood"},{"key":"2023020312104897200_BCJ-2021-0608CC3","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1128\/MCB.15.10.5531","article-title":"Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis","volume":"15","year":"1995","journal-title":"Mol. Cell. Biol."},{"key":"2023020312104897200_BCJ-2021-0608CC4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/sj.cdd.4400213","article-title":"Downregulation of Bcr-Abl in K562 cells restores susceptibility to apoptosis: characterization of the apoptotic death","volume":"4","year":"1997","journal-title":"Cell Death Differ."},{"key":"2023020312104897200_BCJ-2021-0608CC5","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1182\/blood.V91.5.1700","article-title":"Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3","volume":"91","year":"1998","journal-title":"Blood"},{"key":"2023020312104897200_BCJ-2021-0608CC6","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/sj.onc.1201664","article-title":"Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL","volume":"16","year":"1998","journal-title":"Oncogene"},{"key":"2023020312104897200_BCJ-2021-0608CC7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1023\/a:1009623222534","article-title":"Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells","volume":"5","year":"2000","journal-title":"Apoptosis"},{"key":"2023020312104897200_BCJ-2021-0608CC8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s0014-5793(03)00299-0","article-title":"Comparison of the anti-apoptotic effects of Bcr-Abl, Bcl-2 and Bcl-x(L) following diverse apoptogenic stimuli","volume":"541","year":"2003","journal-title":"FEBS Lett."},{"key":"2023020312104897200_BCJ-2021-0608CC9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3390\/pharmaceutics14010215","article-title":"BCR-ABL1 tyrosine kinase complex signaling transduction: challenges to overcome resistance in chronic myeloid leukemia","volume":"14","year":"2022","journal-title":"Pharmaceutics"},{"key":"2023020312104897200_BCJ-2021-0608CC10","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","article-title":"Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides","volume":"105","year":"2005","journal-title":"Blood"},{"key":"2023020312104897200_BCJ-2021-0608CC11","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1590\/s0100-879x1999000900001","article-title":"The regulation of apoptotic cell death","volume":"32","year":"1999","journal-title":"Braz. J. Med. Biol. Res."},{"key":"2023020312104897200_BCJ-2021-0608CC12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.1365-3083.2011.02513.x","article-title":"Apoptosis: a programme of cell death or cell disposal?","volume":"73","year":"2011","journal-title":"Scand. J. Immunol."},{"key":"2023020312104897200_BCJ-2021-0608CC13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2023020312104897200_BCJ-2021-0608CC14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/s0092-8674(00)00187-2","article-title":"BH3-Only proteins-essential initiators of apoptotic cell death","volume":"103","year":"2000","journal-title":"Cell"},{"key":"2023020312104897200_BCJ-2021-0608CC15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/sj.cdd.4400998","article-title":"Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins","volume":"9","year":"2002","journal-title":"Cell Death Differ."},{"key":"2023020312104897200_BCJ-2021-0608CC16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","article-title":"Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function","volume":"17","year":"2005","journal-title":"Mol. Cell"},{"key":"2023020312104897200_BCJ-2021-0608CC17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.molcel.2005.02.003","article-title":"BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly","volume":"17","year":"2005","journal-title":"Mol. Cell"},{"key":"2023020312104897200_BCJ-2021-0608CC18","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1101\/gad.1304105","article-title":"Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins","volume":"19","year":"2005","journal-title":"Genes Dev."},{"key":"2023020312104897200_BCJ-2021-0608CC19","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.tcb.2016.11.004","article-title":"Bax and Bak pores: are we closing the circle?","volume":"27","year":"2017","journal-title":"Trends Cell Biol."},{"key":"2023020312104897200_BCJ-2021-0608CC20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-3-540-69185-3_3","article-title":"The point of no return: mitochondria, caspases, and the commitment to cell death","volume":"24","year":"1998","journal-title":"Results Probl. Cell Differ."},{"key":"2023020312104897200_BCJ-2021-0608CC21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/sj.cdd.4400354","article-title":"Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death","volume":"5","year":"1998","journal-title":"Cell Death Differ."},{"key":"2023020312104897200_BCJ-2021-0608CC22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.15252\/embj.201488806","article-title":"Differential retrotranslocation of mitochondrial Bax and Bak","volume":"34","year":"2015","journal-title":"EMBO J."},{"key":"2023020312104897200_BCJ-2021-0608CC23","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1083\/jcb.139.5.1281","article-title":"Movement of Bax from the cytosol to mitochondria during apoptosis","volume":"139","year":"1997","journal-title":"J. Cell Biol."},{"key":"2023020312104897200_BCJ-2021-0608CC24","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1073\/pnas.92.12.5287","article-title":"Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2","volume":"92","year":"1995","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2023020312104897200_BCJ-2021-0608CC25","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1182\/blood.v99.12.4531","article-title":"Complementary functions of the antiapoptotic protein A1 and serine\/threonine kinase pim-1 in the BCR\/ABL-mediated leukemogenesis","volume":"99","year":"2002","journal-title":"Blood"},{"key":"2023020312104897200_BCJ-2021-0608CC26","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1084\/jem.191.6.977","article-title":"Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL","volume":"191","year":"2000","journal-title":"J. Exp. Med."},{"key":"2023020312104897200_BCJ-2021-0608CC27","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood.V96.6.2269","article-title":"Bcr\/Abl activates transcription of the Bcl-X gene through STAT5","volume":"96","year":"2000","journal-title":"Blood"},{"key":"2023020312104897200_BCJ-2021-0608CC28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1006\/jmbi.1996.0779","article-title":"Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras","volume":"267","year":"1997","journal-title":"J. Mol. Biol."},{"key":"2023020312104897200_BCJ-2021-0608CC29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1101\/gad.13.4.382","article-title":"The prosurvival Bcl-2 homolog Bfl-1\/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis","volume":"13","year":"1999","journal-title":"Genes Dev."},{"key":"2023020312104897200_BCJ-2021-0608CC30","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1182\/blood-2003-01-0083","article-title":"Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro","volume":"102","year":"2003","journal-title":"Blood"},{"key":"2023020312104897200_BCJ-2021-0608CC31","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1128\/MCB.20.4.1179-1186.2000","article-title":"The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf","volume":"20","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"2023020312104897200_BCJ-2021-0608CC32","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1128\/MCB.24.14.6172-6183.2004","article-title":"Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors","volume":"24","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"2023020312104897200_BCJ-2021-0608CC33","doi-asserted-by":"publisher","first-page":"14907","DOI":"10.1073\/pnas.0606176103","article-title":"Bim and Bad mediate imatinib-induced killing of Bcr\/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic","volume":"103","year":"2006","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2023020312104897200_BCJ-2021-0608CC34","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/sj.cdd.4402168","article-title":"Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia","volume":"14","year":"2007","journal-title":"Cell Death Differ."},{"key":"2023020312104897200_BCJ-2021-0608CC35","doi-asserted-by":"publisher","first-page":"12900","DOI":"10.1074\/jbc.RA120.013364","article-title":"The chaperone Hsp70 is a BH3 receptor activated by the pro-apoptotic Bim to stabilize anti-apoptotic clients","volume":"295","year":"2020","journal-title":"J. Biol. Chem."},{"key":"2023020312104897200_BCJ-2021-0608CC36","doi-asserted-by":"publisher","first-page":"114964","DOI":"10.1016\/j.bcp.2022.114964","article-title":"Bcr-Abl drives the formation of Hsp70\/Bim PPI to stabilize oncogenic clients and prevent cells from undergoing apoptosis","volume":"198","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"2023020312104897200_BCJ-2021-0608CC37","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.ejca.2009.04.005","article-title":"Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia","volume":"45","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"2023020312104897200_BCJ-2021-0608CC38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","year":"2000","journal-title":"J. Clin. Invest."},{"key":"2023020312104897200_BCJ-2021-0608CC39","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","year":"2018","journal-title":"Am. J. Hematol."},{"key":"2023020312104897200_BCJ-2021-0608CC40","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"2023020312104897200_BCJ-2021-0608CC41","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"2023020312104897200_BCJ-2021-0608CC42","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"2023020312104897200_BCJ-2021-0608CC43","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/j.leukres.2003.10.007","article-title":"Molecular mechanisms of resistance of leukemia to imatinib mesylate","volume":"28","year":"2004","journal-title":"Leuk. Res."},{"key":"2023020312104897200_BCJ-2021-0608CC44","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1532\/ijh97.04032","article-title":"Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease","volume":"79","year":"2004","journal-title":"Int. J. Hematol."},{"key":"2023020312104897200_BCJ-2021-0608CC45","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2023020312104897200_BCJ-2021-0608CC46","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","year":"2021","journal-title":"Leukemia"},{"key":"2023020312104897200_BCJ-2021-0608CC47","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"2023020312104897200_BCJ-2021-0608CC48","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"2023020312104897200_BCJ-2021-0608CC49","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/j.clml.2016.03.003","article-title":"Comparative effectiveness of newer tyrosine kinase inhibitors versus imatinib in the first-line treatment of chronic-phase chronic myeloid leukemia across risk groups: a systematic review and meta-analysis of eight randomized trials","volume":"16","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"2023020312104897200_BCJ-2021-0608CC50","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1158\/1078-0432.CCR-13-1610","article-title":"Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies","volume":"20","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"2023020312104897200_BCJ-2021-0608CC51","doi-asserted-by":"publisher","first-page":"x274","DOI":"10.1093\/annonc\/mdl273","article-title":"Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors","volume":"17","year":"2006","journal-title":"Ann. Oncol."},{"key":"2023020312104897200_BCJ-2021-0608CC52","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/MOH.0000000000000403","article-title":"Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents","volume":"25","year":"2018","journal-title":"Curr. Opin. Hematol."},{"key":"2023020312104897200_BCJ-2021-0608CC53","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors","volume":"31","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"2023020312104897200_BCJ-2021-0608CC54","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"2023020312104897200_BCJ-2021-0608CC55","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/s1535-6108(02)00096-x","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","year":"2002","journal-title":"Cancer Cell"},{"key":"2023020312104897200_BCJ-2021-0608CC56","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"2023020312104897200_BCJ-2021-0608CC57","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","year":"2011","journal-title":"Blood"},{"key":"2023020312104897200_BCJ-2021-0608CC58","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","year":"2014","journal-title":"Leuk. Res"},{"key":"2023020312104897200_BCJ-2021-0608CC59","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","year":"2003","journal-title":"Blood"},{"key":"2023020312104897200_BCJ-2021-0608CC60","doi-asserted-by":"publisher","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","year":"2005","journal-title":"Cancer Res."},{"key":"2023020312104897200_BCJ-2021-0608CC61","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-3-319-97746-1_6","article-title":"Preservation of quiescent chronic myelogenous leukemia stem cells by the bone marrow microenvironment","volume":"1100","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"2023020312104897200_BCJ-2021-0608CC62","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11899-013-0194-x","article-title":"Genetic events other than BCR-ABL1","volume":"9","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"2023020312104897200_BCJ-2021-0608CC63","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","year":"2007","journal-title":"Blood"},{"key":"2023020312104897200_BCJ-2021-0608CC64","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"28","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"2023020312104897200_BCJ-2021-0608CC65","doi-asserted-by":"publisher","first-page":"840173","DOI":"10.3389\/fimmu.2022.840173","article-title":"Bioactive lipids as chronic myeloid leukemia's potential biomarkers for disease progression and response to tyrosine kinase inhibitors","volume":"13","year":"2022","journal-title":"Front. Immunol."},{"key":"2023020312104897200_BCJ-2021-0608CC66","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3389\/fonc.2019.00939","article-title":"BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia","volume":"9","year":"2019","journal-title":"Front. Oncol."},{"key":"2023020312104897200_BCJ-2021-0608CC67","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s12032-014-0851-5","article-title":"Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia","volume":"31","year":"2014","journal-title":"Med. Oncol."},{"key":"2023020312104897200_BCJ-2021-0608CC68","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1124\/dmd.109.031302","article-title":"Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib","volume":"38","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"2023020312104897200_BCJ-2021-0608CC69","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1179\/1607845414Y.0000000181","article-title":"Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients","volume":"20","year":"2015","journal-title":"Hematology"},{"key":"2023020312104897200_BCJ-2021-0608CC70","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","article-title":"Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia","volume":"21","year":"2012","journal-title":"Cancer Cell"},{"key":"2023020312104897200_BCJ-2021-0608CC71","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.stem.2019.02.018","article-title":"Mesenchymal niche-specific expression of Cxcl12 controls quiescence of treatment-resistant leukemia stem cells","volume":"24","year":"2019","journal-title":"Cell Stem Cell"},{"key":"2023020312104897200_BCJ-2021-0608CC72","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/leu.2014.245","article-title":"Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia","volume":"29","year":"2015","journal-title":"Leukemia"},{"key":"2023020312104897200_BCJ-2021-0608CC73","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/sj.leu.2404549","article-title":"Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase","volume":"21","year":"2007","journal-title":"Leukemia"},{"key":"2023020312104897200_BCJ-2021-0608CC74","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1038\/cddis.2013.309","article-title":"PI3K\/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor","volume":"4","year":"2013","journal-title":"Cell Death Dis."},{"key":"2023020312104897200_BCJ-2021-0608CC75","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","article-title":"Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance","volume":"7","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"2023020312104897200_BCJ-2021-0608CC76","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/leu.2011.325","article-title":"Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors","volume":"26","year":"2012","journal-title":"Leukemia"},{"key":"2023020312104897200_BCJ-2021-0608CC77","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3324\/haematol.2013.098442","article-title":"Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy","volume":"99","year":"2014","journal-title":"Haematologica"},{"key":"2023020312104897200_BCJ-2021-0608CC78","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","year":"2007","journal-title":"Cancer Cell"},{"key":"2023020312104897200_BCJ-2021-0608CC79","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"2023020312104897200_BCJ-2021-0608CC80","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","year":"2012","journal-title":"Cancer Cell"},{"key":"2023020312104897200_BCJ-2021-0608CC81","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/onc.2012.83","article-title":"SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells","volume":"32","year":"2013","journal-title":"Oncogene"},{"key":"2023020312104897200_BCJ-2021-0608CC82","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bcmd.2014.02.008","article-title":"Apoptomirs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance","volume":"53","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"2023020312104897200_BCJ-2021-0608CC83","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition","volume":"6","year":"2016","journal-title":"Cancer Discov."},{"key":"2023020312104897200_BCJ-2021-0608CC84","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/onc.2010.409","article-title":"BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients","volume":"30","year":"2011","journal-title":"Oncogene"},{"key":"2023020312104897200_BCJ-2021-0608CC85","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2174\/156652413804810727","article-title":"PRAME\/EZH2-mediated regulation of TRAIL: a new target for cancer therapy","volume":"13","year":"2013","journal-title":"Curr. Mol. Med."},{"key":"2023020312104897200_BCJ-2021-0608CC86","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling","volume":"122","year":"2005","journal-title":"Cell"},{"key":"2023020312104897200_BCJ-2021-0608CC87","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1182\/blood-2006-12-065599","article-title":"The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia","volume":"110","year":"2007","journal-title":"Blood"},{"key":"2023020312104897200_BCJ-2021-0608CC88","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2217\/epi.15.35","article-title":"Polycomb genes are associated with response to imatinib in chronic myeloid leukemia","volume":"7","year":"2015","journal-title":"Epigenomics"},{"key":"2023020312104897200_BCJ-2021-0608CC89","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3389\/fonc.2018.00555","article-title":"The polycomb BMI1 protein is co-expressed with CD26+ in leukemic stem cells of chronic myeloid leukemia","volume":"8","year":"2018","journal-title":"Front. Oncol."},{"key":"2023020312104897200_BCJ-2021-0608CC90","doi-asserted-by":"publisher","first-page":"10002","DOI":"10.1073\/pnas.1633833100","article-title":"Expression of BCR\/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias","volume":"100","year":"2003","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2023020312104897200_BCJ-2021-0608CC91","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2011-01-327197","article-title":"Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL\/Bcl-2 in Mcl-1-expressing myeloma cells","volume":"118","year":"2011","journal-title":"Blood"},{"key":"2023020312104897200_BCJ-2021-0608CC92","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/leu.2015.184","article-title":"BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics","volume":"30","year":"2016","journal-title":"Leukemia"},{"key":"2023020312104897200_BCJ-2021-0608CC93","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","article-title":"High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","volume":"81","year":"1993","journal-title":"Blood"},{"key":"2023020312104897200_BCJ-2021-0608CC94","first-page":"1758","article-title":"The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics","volume":"5","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"2023020312104897200_BCJ-2021-0608CC95","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.18632\/oncotarget.1306","article-title":"Hoxa9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia","volume":"4","year":"2013","journal-title":"Oncotarget"},{"key":"2023020312104897200_BCJ-2021-0608CC96","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/nrd2658","article-title":"BCL-2 family antagonists for cancer therapy","volume":"7","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"2023020312104897200_BCJ-2021-0608CC97","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1182\/asheducation-2005.1.226","article-title":"Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer","volume":"2005","year":"2005","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"2023020312104897200_BCJ-2021-0608CC98","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1021\/jm030190z","article-title":"Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte\/leukemia-2 proteins","volume":"46","year":"2003","journal-title":"J. Med. Chem."},{"key":"2023020312104897200_BCJ-2021-0608CC99","doi-asserted-by":"publisher","first-page":"20075","DOI":"10.18632\/oncotarget.24744","article-title":"S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth","volume":"9","year":"2018","journal-title":"Oncotarget"},{"key":"2023020312104897200_BCJ-2021-0608CC100","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","year":"2013","journal-title":"Nat. Med."},{"key":"2023020312104897200_BCJ-2021-0608CC101","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","year":"2008","journal-title":"Cancer Res."},{"key":"2023020312104897200_BCJ-2021-0608CC102","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","year":"2005","journal-title":"Nature"},{"key":"2023020312104897200_BCJ-2021-0608CC103","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/cdd.2008.25","article-title":"A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells","volume":"15","year":"2008","journal-title":"Cell Death Differ."},{"key":"2023020312104897200_BCJ-2021-0608CC104","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1158\/0008-5472.CAN-07-5031","article-title":"Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer","volume":"68","year":"2008","journal-title":"Cancer Res."},{"key":"2023020312104897200_BCJ-2021-0608CC105","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"2023020312104897200_BCJ-2021-0608CC106","doi-asserted-by":"publisher","first-page":"E1288","DOI":"10.1073\/pnas.1411848112","article-title":"Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer","volume":"112","year":"2015","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2023020312104897200_BCJ-2021-0608CC107","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-07-4622","article-title":"Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models","volume":"14","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"2023020312104897200_BCJ-2021-0608CC108","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13058-020-01374-8","article-title":"Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer","volume":"22","year":"2020","journal-title":"Breast Cancer Res."},{"key":"2023020312104897200_BCJ-2021-0608CC109","doi-asserted-by":"publisher","first-page":"5807","DOI":"10.1182\/blood-2011-12-400929","article-title":"Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells","volume":"119","year":"2012","journal-title":"Blood"},{"key":"2023020312104897200_BCJ-2021-0608CC110","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed anuclear cell death delimits platelet life span","volume":"128","year":"2007","journal-title":"Cell"},{"key":"2023020312104897200_BCJ-2021-0608CC111","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2023020312104897200_BCJ-2021-0608CC112","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41419-021-03500-6","article-title":"The application of BH3 mimetics in myeloid leukemias","volume":"12","year":"2021","journal-title":"Cell Death Dis."},{"key":"2023020312104897200_BCJ-2021-0608CC113","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12885-017-3383-5","article-title":"Potential mechanisms of resistance to venetoclax and strategies to circumvent it","volume":"17","year":"2017","journal-title":"BMC Cancer"},{"key":"2023020312104897200_BCJ-2021-0608CC114","doi-asserted-by":"publisher","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia","volume":"6","year":"2016","journal-title":"Sci. Rep."},{"key":"2023020312104897200_BCJ-2021-0608CC115","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","year":"2019","journal-title":"Cancer Discov."},{"key":"2023020312104897200_BCJ-2021-0608CC116","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","year":"2020","journal-title":"Blood"},{"key":"2023020312104897200_BCJ-2021-0608CC117","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2005.09.010","article-title":"Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy","volume":"44","year":"2006","journal-title":"J. Hepatol."},{"key":"2023020312104897200_BCJ-2021-0608CC118","doi-asserted-by":"publisher","first-page":"7904","DOI":"10.1038\/sj.onc.1210587","article-title":"Sphingosine kinase-1 mediates BCR\/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells","volume":"26","year":"2007","journal-title":"Oncogene"},{"key":"2023020312104897200_BCJ-2021-0608CC119","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1101\/gad.182980.111","article-title":"Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia","volume":"26","year":"2012","journal-title":"Genes Dev."},{"key":"2023020312104897200_BCJ-2021-0608CC120","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1101\/gad.232009.113","article-title":"Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53","volume":"28","year":"2014","journal-title":"Genes Dev."},{"key":"2023020312104897200_BCJ-2021-0608CC121","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41419-017-0035-2","article-title":"MCL-1 is a prognostic indicator and drug target in breast cancer","volume":"9","year":"2018","journal-title":"Cell Death Dis."},{"key":"2023020312104897200_BCJ-2021-0608CC122","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","year":"2016","journal-title":"Nature"},{"key":"2023020312104897200_BCJ-2021-0608CC123","doi-asserted-by":"publisher","first-page":"13762","DOI":"10.1021\/acs.jmedchem.0c01234","article-title":"Discovery of S64315, a potent and selective Mcl-1 inhibitor","volume":"63","year":"2020","journal-title":"J. Med. Chem."},{"key":"2023020312104897200_BCJ-2021-0608CC124","doi-asserted-by":"publisher","first-page":"eaam7049","DOI":"10.1126\/scitranslmed.aam7049","article-title":"Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer","volume":"9","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"2023020312104897200_BCJ-2021-0608CC125","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-18-0549","article-title":"Tyrosine kinase inhibitors increase MCL1 degradation and in combination with BCLXL\/BCL2 inhibitors drive prostate cancer apoptosis","volume":"24","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"2023020312104897200_BCJ-2021-0608CC126","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41419-020-2379-2","article-title":"MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X(L) expression","volume":"11","year":"2020","journal-title":"Cell Death Dis."},{"key":"2023020312104897200_BCJ-2021-0608CC127","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41419-020-2646-2","article-title":"MCL1 inhibitors S63845\/MIK665 plus navitoclax synergistically kill difficult-to-treat melanoma cells","volume":"11","year":"2020","journal-title":"Cell Death Dis."},{"key":"2023020312104897200_BCJ-2021-0608CC128","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","year":"2018","journal-title":"Nat. Commun."},{"key":"2023020312104897200_BCJ-2021-0608CC129","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1158\/1538-7445.AM2021-983","article-title":"Abstract 983: preclinical characterization of PRT1419, a potent, selective and orally available inhibitor of MCL1","volume":"81","year":"2021","journal-title":"Cancer Res."},{"key":"2023020312104897200_BCJ-2021-0608CC130","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","year":"2018","journal-title":"Cancer Discov."},{"key":"2023020312104897200_BCJ-2021-0608CC131","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.1158\/1538-7445.AM2020-6218","article-title":"Abstract 6218: discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor","volume":"80","year":"2020","journal-title":"Cancer Res."},{"key":"2023020312104897200_BCJ-2021-0608CC132","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","year":"2018","journal-title":"Cancer Discov."},{"key":"2023020312104897200_BCJ-2021-0608CC133","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/ejh.13492","article-title":"Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML","volume":"105","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"2023020312104897200_BCJ-2021-0608CC134","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","article-title":"A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition","volume":"12","year":"2013","journal-title":"Cell Stem Cell"},{"key":"2023020312104897200_BCJ-2021-0608CC135","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nm.2713","article-title":"A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer","volume":"18","year":"2012","journal-title":"Nat. Med"},{"key":"2023020312104897200_BCJ-2021-0608CC136","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/leu.2013.151","article-title":"Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target","volume":"27","year":"2013","journal-title":"Leukemia"},{"key":"2023020312104897200_BCJ-2021-0608CC137","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/annonc\/mdv110","article-title":"A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia","volume":"26","year":"2015","journal-title":"Ann. Oncol."},{"key":"2023020312104897200_BCJ-2021-0608CC138","doi-asserted-by":"publisher","first-page":"355ra117","DOI":"10.1126\/scitranslmed.aag1180","article-title":"Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells","volume":"8","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"2023020312104897200_BCJ-2021-0608CC139","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.v99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","year":"2002","journal-title":"Blood"},{"key":"2023020312104897200_BCJ-2021-0608CC140","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","year":"2006","journal-title":"Blood"},{"key":"2023020312104897200_BCJ-2021-0608CC141","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.3390\/cancers13061311","article-title":"Targeting chronic myeloid leukemia stem\/progenitor cells using venetoclax-loaded immunoliposome","volume":"13","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2023020312104897200_BCJ-2021-0608CC142","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1365-2141.2007.06899.x","article-title":"ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms","volume":"140","year":"2008","journal-title":"Br. J. Haematol."},{"key":"2023020312104897200_BCJ-2021-0608CC143","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41420-022-01211-1","article-title":"BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia","volume":"8","year":"2022","journal-title":"Cell Death Discov."},{"key":"2023020312104897200_BCJ-2021-0608CC144","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejps.2015.01.003","article-title":"Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition","volume":"70","year":"2015","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["Biochemical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/480\/2\/161\/942547\/bcj-2021-0608c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/480\/2\/161\/942547\/bcj-2021-0608c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T12:11:40Z","timestamp":1675426300000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemj\/article\/480\/2\/161\/232520\/BH3-mimetics-and-TKI-combined-therapy-for-Chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":144,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1,31]]}},"URL":"https:\/\/doi.org\/10.1042\/bcj20210608","relation":{},"ISSN":["0264-6021","1470-8728"],"issn-type":[{"value":"0264-6021","type":"print"},{"value":"1470-8728","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,31]]}}}